Itching, Rash and the One Skin Reaction That Means Stop the Drug

The short version

Itching and rash on a GLP-1 are real, they are reported more often by women than men, and they are uncommon. Almost all of it is nuisance. A small and specific subset is not, and the difference is not how bad it feels — it is what kind of reaction it is.

That distinction is the whole page, so it goes first: swelling of the lips, tongue, face or throat, or difficulty breathing, is not an itch. It is a hypersensitivity reaction, and the label's instruction is to stop the drug and seek medical advice promptly. Everything else below is about the ordinary kind.

What the label actually says, which is not much

It is worth being straight about how thin the evidence base is here, because most pages on this subject imply a precision that does not exist.

Across the entire Wegovy prescribing information — a document of roughly 943 kilobytes covering both the injection and the tablet — the word "pruritus," the clinical term for itching, appears once. There is no adult adverse-reaction row for itching to quote, because the trials did not report one at a rate high enough to list.

Rash and urticaria do appear in one adverse-reaction table, and it is the pediatric one: in the trial of patients aged 12 and older, rash was reported in 3% on semaglutide against 0% on placebo, and urticaria likewise 3% against 0%.

What the label does address directly is the serious end. Under Warnings and Precautions, it records that anaphylactic reactions and angioedema have been reported postmarketing, with the instruction to discontinue if one is suspected and promptly seek medical advice.

So the label's position, fairly summarized: ordinary itching is not a listed adult adverse reaction, and severe allergic reactions are rare but real and are a reason to stop.

The largest analysis, and the number in it that misleads

The most substantial dataset on GLP-1 skin reactions is a 2026 analysis of the FDA Adverse Event Reporting System covering 2018 to 2024, examining semaglutide, liraglutide, exenatide and dulaglutide¹.

Two of its findings matter to you.

Skin reactions are reported more often in women. Cutaneous adverse events were reported in up to 8.16% of GLP-1 receptor agonist cases, more often in females, with a mean patient age of 60¹. If you are a woman who has developed an itch on one of these drugs, you are in the group that reports it most.

But the class compares favorably. Using DPP-4 inhibitors as the comparator, the proportional reporting ratio for cutaneous events was 0.27 (95% CI, 0.257 to 0.284) — meaning these reactions were reported proportionally less often for GLP-1 drugs than for the comparison class. Within the GLP-1 group, semaglutide carried the highest rate and dulaglutide the lowest; exenatide showed increased odds (OR 5.01; 95% CI, 4.69 to 5.35) while liraglutide and semaglutide showed decreased odds¹.

Now the caveat that has to travel with that 8.16%, because without it the number is misleading in a specific way.

FAERS is a spontaneous reporting system with no denominator. It collects reports that someone chose to file; it does not know how many people took the drug. So "8.16% of cases" means 8.16% of the reports submitted, not 8.16% of patients. It cannot tell you your odds. It is good for comparing drugs against each other — which is exactly what the proportional reporting ratio does — and bad for estimating how likely something is to happen to you.

The authors' own conclusion is appropriately modest: cutaneous adverse events are infrequent but vary by drug, and greater awareness may improve patient counseling¹.

The kinds of itch, and which is which

Reviews of the dermatologic literature on these drugs describe a spread of findings rather than one syndrome^2,3. In practice what women describe falls into a few recognizable patterns, and telling them apart changes what you do.

Injection-site irritation. Redness, a small raised patch, itching confined to where the needle went, appearing within hours and settling within a day or two. Common, unremarkable, and the label's own instruction addresses it directly: rotate injection sites with each dose. This is the most frequent thing people mean by "the shot made me itchy."

Generalized dry-skin itch. Diffuse, worse on the shins and forearms, worse in winter, worse after hot showers, and not tied to the injection site or the day of the dose. This is very often not a drug reaction at all in the immunological sense — it tracks with the reduced food and fluid intake, the weight loss itself, and the season. It is also the type most helped by unglamorous measures.

Urticaria — hives. Raised, pale, intensely itchy welts that move around and individually come and go within hours. This one is a histamine-mediated reaction, and it belongs in a message to your prescriber rather than a bottle of lotion, because it sits on the same spectrum as the reactions the label tells you to stop for.

Angioedema. Swelling of the lips, tongue, eyelids, face or throat, often with little or no itch at all. This is the emergency, and it is the one that does not announce itself as a skin problem. A 2026 case report describes angioedema following an accidental semaglutide dosing error⁴, and the label lists it among postmarketing reports with a discontinue instruction.

Rarer things. A review in Archives of Dermatological Research catalogs uncommon cutaneous reactions reported with this drug class⁵. They exist, they are genuinely rare, and their main practical use to you is knowing that a dermatologist has options if a rash does not fit any of the ordinary patterns.

What helps the ordinary kind

None of this has been tested against GLP-1-associated itch specifically. It is standard dermatologic management applied to a new context, and it is fair to say so.

Rotate the site, and give it more room than you think. The label lists abdomen, thigh and upper arm as acceptable, and instructs rotating with each dose. Working through a genuine sequence rather than favoring one comfortable spot is the single most effective change for injection-site itch.

Moisturize on damp skin, not dry. Within three minutes of a shower, on skin still slightly wet. This has a larger effect than which product you use.

Turn the water down. Hot showers strip the skin barrier and are a very common trigger for the diffuse type — and a hot shower is often the only ten minutes of a mother's day that belong to her, which is why this advice is so widely ignored.

Check what else changed. Rapid weight loss changes how clothes sit, which changes where fabric rubs. New friction from a waistband that now sits differently produces an itch that has nothing to do with the drug's chemistry.

Watch your fluid intake honestly. Appetite suppression reduces drinking as well as eating, and mild dehydration makes skin itch.

If itching is accompanied by dark urine, pale stools or yellowing of the eyes, that is a different problem entirely and needs same-day medical attention rather than a moisturizer.

Where this sits

The honest position is unsatisfying and it is better than false precision.

Skin reactions on these drugs are real and are reported disproportionately by women. They are, as a class, reported proportionally less often than for a comparator drug class. There is no reliable published figure for how likely ordinary itching is, because the trials did not report it and the database that captures it cannot produce a rate.

For most women the itch is a nuisance that responds to site rotation, moisturizer and cooler water. For a small number it is the leading edge of a hypersensitivity reaction, and that is the one worth being able to recognize — not because it is likely, but because it is the only version where what you do next actually matters.